Findings

What do systematic reviews say?

4 questions · 4 findings · 1 reviews · Vascular

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 3 · 75%Moderate 1 · 25%High 0 · 0%

Adverse events(during · children or adults with Types I or II HAE

Berotralstat showed no clear difference in adverse events(during compared with placebo or active control (moderate certainty).

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
RR 1.03 [0.88, 1.22]
3 studies · 128 participants
Moderate

Adverse events(during · children or adults with Types I or II HAE

Plasma‐derived C1 esterase inhibitor showed no clear difference in adverse events(during compared with placebo or active control (low certainty).

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
RR 1.05 [0.78, 1.42]
1 study · 71 participants
Low

Adverse events(during · children or adults with Types I or II HAE

Recombinant human C1 esterase inhibitor showed no clear difference in adverse events(during compared with placebo or active control (low certainty).

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
RR 1.39 [0.71, 2.7]
1 study · 29 participants
Low

Adverse events(during · children or adults with Types I or II HAE

Lanadelumab showed no clear difference in adverse events(during compared with placebo or active control (low certainty).

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
RR 1.07 [0.77, 1.47]
2 studies · 158 participants
Low